

APPENDIX F

Vaccine Safety

The Vaccine Adverse Event Reporting System (VAERS) F-1

Table of Reportable Events Following Vaccination F-2

Vaccine Adverse Event Reporting System (VAERS) Form F-4

The Vaccine Injury Compensation Program (VICP) F-6

The VICP Vaccine Injury Table F-7

**“Qualifications and Aids to Interpretation of Vaccine
Injury Table” F-8**

Appendix F

The Vaccine Adverse Event Reporting System (VAERS)

VAERS is a national vaccine safety surveillance program co-sponsored by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). VAERS collects and analyzes information from reports of adverse events following immunization. Since 1990, VAERS has received over 123,000 reports, most of which describe mild side effects such as fever. Very rarely, people experience serious adverse events following immunization. By monitoring such events, VAERS can help to identify important new safety concerns.

Reporting to VAERS

Who can file a VAERS report: Anyone can submit a VAERS report. Most reports are sent in by vaccine manufacturers (42%) and health care providers (30%). The rest are submitted by state immunization programs (12%), vaccine recipients or their parent/guardians (7%), and other sources (9%).

What adverse events should be reported: VAERS encourages the reporting of any clinically significant adverse event that occurs after the administration of any vaccine licensed in the United States. Report such events even if you are unsure whether a vaccine caused them.

The National Childhood Vaccine Injury Act (NCVIA) requires health care providers to report:

- Any event listed by the vaccine manufacturer as a contraindication to subsequent doses of the vaccine.
- Any event listed in the Reportable Events Table that occurs within the specified time period after vaccination.

A copy of the Reportable Events Table can be found on the next page (F-2), or obtained by calling VAERS at 1-800-822-7967 or by downloading it from <http://vaers.hhs.gov/pubs.htm>.

Filing a VAERS report: Use a VAERS report form (see page F-4) to report any adverse event. You can get pre-addressed postage paid report forms by calling VAERS at 1-800-822-7967, or download a printable copy of the VAERS form from the following Internet sites:

- The VAERS Web site at <http://vaers.hhs.gov/>
- The Food and Drug Administration's Web site at www.fda.gov/cber/vaers/vaers.htm
- The Centers for Disease Control and Prevention Web site at www.cdc.gov/vaccines/

Instructions are included with the form. You may use a photocopy of the VAERS form to submit a report.

For more information:

- Send e-mail inquiries to info@vaers.org
- Visit the VAERS Web site at: <http://vaers.hhs.gov>
- Call the toll-free VAERS information line at (800) 822-7967
- Fax inquiries to the toll-free information fax line at (877) 721-0366

This information has been adapted from the VAERS website (<http://vaers.hhs.gov>).

VAERS Table of Reportable Events Following Vaccination*

Vaccine/Toxoid	Event	Interval from Vaccination
Tetanus in any combination; DTaP, DTP, DTP-HiB, DT, Td, TT, Tdap	A. Anaphylaxis or anaphylactic shock B. Brachial neuritis C. Any acute complications or sequela (including death) of above events D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	7 days 28 days Not applicable See package insert
Pertussis in any combination; DTaP, DTP, DTP-HiB, P, Tdap	A. Anaphylaxis or anaphylactic shock B. Encephalopathy (or encephalitis) C. Any acute complications or sequela (including death) of above events D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	7 days 7 days Not applicable See package insert
Measles, mumps and rubella in any combination; MMR, MR, M, MMRV, R	A. Anaphylaxis or anaphylactic shock B. Encephalopathy (or encephalitis) C. Any acute complications or sequela (including death) of above events D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	7 days 15 days Not applicable See package insert
Rubella in any combination; MMR, MMRV, MR, R	A. Chronic arthritis B. Any acute complications or sequela (including death) of above event C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	42 days Not applicable See package insert
Measles in any combination; MMR, MMRV, MR, M	A. Thrombocytopenic purpura B. Vaccine-strain measles viral infection in an immunodeficient recipient C. Any acute complications or sequela (including death) of above events D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	7-30 days 6 months Not applicable See package insert
Oral Polio (OPV)	A. Paralytic polio – in a non-immunodeficient recipient – in an immunodeficient recipient – in a vaccine associated community case B. Vaccine-strain polio viral infection – in a non-immunodeficient recipient – in an immunodeficient recipient – in a vaccine associated community case C. Any sequela (including death) of above events D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	30 days 6 months Not applicable 30 days 6 months Not applicable Not applicable See package insert
Inactivated Polio (IPV)	A. Anaphylaxis or anaphylactic shock B. Any sequela (including death) of the above event C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	7 days Not applicable See package insert
Hepatitis B	A. Anaphylaxis or anaphylactic shock B. Any acute complications or sequela (including death) of the above event C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	7 days Not applicable See package insert
Hemophilus influenzae type b (conjugate)	A. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	See package insert
Varicella	A. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	See package insert
Rotavirus	A. Intussusception B. Any acute complications or sequela (including death) of the above event C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	30 days Not applicable See package insert
Pneumococcal conjugate	A. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	See package insert
Hepatitis A	A. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	See package insert
Influenza	A. Events described in manufacturer's package insert as contraindications to additional doses of vaccine	See package insert

* **Effective date: July 01, 2005.** The Reportable Events Table (RET) reflects what is reportable by law (42 USC 300aa-25) to the Vaccine Adverse Event Reporting System (VAERS) including conditions found in the manufacturers package insert. In addition, individuals are encouraged to report **any** clinically significant or unexpected events (even if you are not certain the vaccine caused the event) for **any** vaccine, whether or not it is listed on the RET. Manufacturers are also required by regulation (21CFR 600.80) to report to the VAERS program all adverse events made known to them for any vaccine.

Reportable Events Table Definitions

Anaphylaxis and anaphylactic shock. Anaphylaxis and anaphylactic shock mean an acute, severe, and potentially lethal systemic allergic reaction. Most cases resolve without sequelae. Signs and symptoms begin minutes to a few hours after exposure. Death, if it occurs, usually results from airway obstruction caused by laryngeal edema or bronchospasm and may be associated with cardiovascular collapse.

Brachial neuritis is defined as dysfunction limited to the upper extremity nerve plexus (i.e., its trunks, division, or cords) without involvement of other peripheral (e.g., nerve roots or a single peripheral nerve) or central (e.g., spinal cord) nervous system structures. A deep, steady, often severe aching pain in the shoulder and upper arm usually heralds onset of the condition. The pain is followed in days or weeks by weakness and atrophy in upper extremity muscle groups. Sensory loss may accompany the motor deficits, but is generally a less notable clinical feature.

Encephalopathy. For purposes of the Reportable Events Table, a vaccine recipient shall be considered to have suffered an encephalopathy only if such recipient manifests, within the applicable period, an injury meeting the description below of an acute encephalopathy, and then a chronic encephalopathy persists in such person for more than 6 months beyond the date of vaccination.

1. An **acute encephalopathy** is one that is sufficiently severe so as to require hospitalization (whether or not hospitalization occurred).
 - a. For **children less than 18 months of age** who present without an associated seizure event, an acute encephalopathy is indicated by a "significantly decreased level of consciousness" (see "D" below) lasting for at least 24 hours. Those children less than 18 months of age who present following a seizure shall be viewed as having an acute encephalopathy if their significantly decreased level of consciousness persists beyond 24 hours and cannot be attributed to a postictal state (seizure) or medication.
 - b. For adults and **children 18 months of age** or older, an acute encephalopathy is one that persists for at least 24 hours and is characterized by at least two of the following:
 - i. A significant change in mental status that is not medication related: specifically a confusional state, or a delirium, or a psychosis;
 - ii. A significantly decreased level of consciousness, which is independent of a seizure and cannot be attributed to the effects of medication; and
 - iii. A seizure associated with loss of consciousness.
 - c. Increased intracranial **pressure** may be a clinical feature of acute encephalopathy in any age group.
2. A "**significantly decreased level of consciousness**" is indicated by the presence of at least one of the following clinical signs for at least 24 hours or greater:
 - a. Decreased or absent response to environment (responds, if at all, only to loud voice or painful stimuli);
 - b. Decreased or absent eye contact (does not fix gaze upon family members or other individuals); or
 - c. Inconsistent or absent responses to external stimuli (does not recognize familiar people or things).

The following clinical features alone, or in combination, do not demonstrate an acute encephalopathy or a significant change in either mental status or level of consciousness as described above: Sleepiness, irritability (fussiness), high-pitched and unusual screaming, persistent inconsolable crying, and bulging fontanelle. Seizures in themselves are not sufficient to constitute a diagnosis of encephalopathy. In the absence of other evidence of an acute encephalopathy, seizures shall not be viewed as the first symptom or manifestation of the onset of an acute encephalopathy.

3. **Chronic Encephalopathy** occurs when a change in mental or neurologic status, first manifested during the applicable time period, persists for a period of at least 6 months from the date of vaccination. Individuals who return to a normal neurologic state after the acute encephalopathy shall not be presumed to have suffered residual neurologic damage from that event; any subsequent chronic encephalopathy shall not be presumed to be a sequela of the acute encephalopathy. If a preponderance of the evidence indicates that a child's chronic encephalopathy is secondary to genetic, prenatal or perinatal factors, that chronic encephalopathy shall not be considered to be a condition set forth in the Table. An encephalopathy shall not be considered to be a condition set forth in the Table if it is shown that the encephalopathy was caused by an infection, a toxin, a metabolic disturbance, a structural lesion, a genetic disorder or trauma (without regard to whether the cause of the infection, toxin, trauma, metabolic disturbance, structural lesion or genetic disorder is known).

Chronic Arthritis. For purposes of the Reportable Events Table, chronic arthritis may be found in a person with no history in the 3 years prior to vaccination of arthropathy (joint disease) on the basis of:

- a. Medical documentation, recorded within 30 days after the onset, of objective signs of acute arthritis (joint swelling) that occurred between 7 and 42 days after a rubella vaccination; and
- b. Medical documentation (recorded within 3 years after the onset of acute arthritis) of the persistence of objective signs of intermittent or continuous arthritis for more than 6 months following vaccination.
- c. Medical documentation of an antibody response to the rubella virus.

The following shall not be considered as chronic arthritis: Musculoskeletal disorders such as diffuse connective tissue diseases (including but not limited to rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disease, polymyositis/dermatomyositis, fibromyalgia, necrotizing vasculitis and vasculopathies and Sjogren's Syndrome), degenerative joint disease, infectious agents other than rubella (whether by direct invasion or as an immune reaction), metabolic and endocrine diseases, trauma, neoplasms, neuropathic disorders, bone and cartilage disorders and arthritis associated with ankylosing spondylitis, psoriasis, inflammatory bowel disease, Reiter's syndrome, or blood disorders.


Arthralgia (joint pain) or stiffness without joint swelling shall not be viewed as chronic arthritis.

Sequela. The term "sequela" means a condition or event, which was actually caused by a condition listed in the Reportable Events Table.

Appendix F

WEBSITE: www.vaers.hhs.gov E-MAIL: info@vaers.org

FAX: 1-877-721-0366

 VACCINE ADVERSE EVENT REPORTING SYSTEM 24 Hour Toll-Free Information 1-800-822-7967 P.O. Box 1100, Rockville, MD 20849-1100 PATIENT IDENTITY KEPT CONFIDENTIAL		For CDC/FDA Use Only VAERS Number _____ Date Received _____			
Patient Name: Last _____ First _____ M.I. _____ Address _____ _____ _____ City _____ State _____ Zip _____ Telephone no. (____) _____		Vaccine administered by (Name): _____ Responsible Physician _____ Facility Name/Address _____ _____ _____ City _____ State _____ Zip _____ Telephone no. (____) _____			
Form completed by (Name): _____ Relation <input type="checkbox"/> Vaccine Provider <input type="checkbox"/> Patient/Parent to Patient <input type="checkbox"/> Manufacturer <input type="checkbox"/> Other Address (if different from patient or provider) _____ _____ _____ City _____ State _____ Zip _____ Telephone no. (____) _____					
1. State	2. County where administered	3. Date of birth mm / dd / yy	4. Patient age	5. Sex <input type="checkbox"/> M <input type="checkbox"/> F	6. Date form completed mm / dd / yy
7. Describe adverse event(s) (symptoms, signs, time course) and treatment, if any			8. Check all appropriate: <input type="checkbox"/> Patient died (date mm / dd / yy) <input type="checkbox"/> Life threatening illness <input type="checkbox"/> Required emergency room/doctor visit <input type="checkbox"/> Required hospitalization (____ days) <input type="checkbox"/> Resulted in prolongation of hospitalization <input type="checkbox"/> Resulted in permanent disability <input type="checkbox"/> None of the above		
9. Patient recovered <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> UNKNOWN			10. Date of vaccination mm / dd / yy AM Time _____ PM	11. Adverse event onset mm / dd / yy AM Time _____ PM	
12. Relevant diagnostic tests/laboratory data					
13. Enter all vaccines given on date listed in no. 10					
Vaccine (type)		Manufacturer	Lot number	Route/Site	No. Previous Doses
a. _____		_____	_____	_____	_____
b. _____		_____	_____	_____	_____
c. _____		_____	_____	_____	_____
d. _____		_____	_____	_____	_____
14. Any other vaccinations within 4 weeks prior to the date listed in no. 10					
Vaccine (type)		Manufacturer	Lot number	Route/Site	No. Previous doses
a. _____		_____	_____	_____	_____
b. _____		_____	_____	_____	_____
15. Vaccinated at: <input type="checkbox"/> Private doctor's office/hospital <input type="checkbox"/> Public health clinic/hospital		<input type="checkbox"/> Military clinic/hospital <input type="checkbox"/> Other/unknown		16. Vaccine purchased with: <input type="checkbox"/> Private funds <input type="checkbox"/> Military funds <input type="checkbox"/> Public funds <input type="checkbox"/> Other/unknown	
17. Other medications					
18. Illness at time of vaccination (specify)			19. Pre-existing physician-diagnosed allergies, birth defects, medical conditions (specify)		
20. Have you reported this adverse event previously? <input type="checkbox"/> No <input type="checkbox"/> To health department <input type="checkbox"/> To doctor <input type="checkbox"/> To manufacturer		Only for children 5 and under			
		22. Birth weight _____ lb. _____ oz.		23. No. of brothers and sisters	
21. Adverse event following prior vaccination (check all applicable, specify) Adverse Event Onset Age Type Vaccine Dose no. in series <input type="checkbox"/> In patient <input type="checkbox"/> In brother or sister		Only for reports submitted by manufacturer/immunization project			
		24. Mfr./imm. proj. report no.		25. Date received by mfr./imm.proj.	
		26. 15 day report? <input type="checkbox"/> Yes <input type="checkbox"/> No		27. Report type <input type="checkbox"/> Initial <input type="checkbox"/> Follow-Up	
Health care providers and manufacturers are required by law (42 USC 300aa-25) to report reactions to vaccines listed in the Table of Reportable Events Following Immunization. Reports for reactions to other vaccines are voluntary except when required as a condition of immunization grant awards.					

Form VAERS-1(FDA)

"Fold in thirds, tape & mail — DO NOT STAPLE FORM"



NO POSTAGE
NECESSARY
IF MAILED
IN THE
UNITED STATES
OR APO/FPO

BUSINESS REPLY MAIL

FIRST-CLASS MAIL PERMIT NO. 1895 ROCKVILLE, MD

POSTAGE WILL BE PAID BY ADDRESSEE



VAERS

P.O. Box 1100
Rockville MD 20849-1100



DIRECTIONS FOR COMPLETING FORM

(Additional pages may be attached if more space is needed.)

GENERAL

- Use a separate form for each patient. Complete the form to the best of your abilities. Items 3, 4, 7, 8, 10, 11, and 13 are considered essential and should be completed whenever possible. Parents/Guardians may need to consult the facility where the vaccine was administered for some of the information (such as manufacturer, lot number or laboratory data.)
- Refer to the Reportable Events Table (RET) for events mandated for reporting by law. Reporting for other serious events felt to be related but not on the RET is encouraged.
- Health care providers other than the vaccine administrator (VA) treating a patient for a suspected adverse event should notify the VA and provide the information about the adverse event to allow the VA to complete the form to meet the VA's legal responsibility.
- These data will be used to increase understanding of adverse events following vaccination and will become part of CDC Privacy Act System 09-20-0136, "Epidemiologic Studies and Surveillance of Disease Problems". Information identifying the person who received the vaccine or that person's legal representative will not be made available to the public, but may be available to the vaccinee or legal representative.
- Postage will be paid by addressee. Forms may be photocopied (must be front & back on same sheet).

SPECIFIC INSTRUCTIONS

Form Completed By: To be used by parents/guardians, vaccine manufacturers/distributors, vaccine administrators, and/or the person completing the form on behalf of the patient or the health professional who administered the vaccine.

- Item 7: Describe the suspected adverse event. Such things as temperature, local and general signs and symptoms, time course, duration of symptoms, diagnosis, treatment and recovery should be noted.
- Item 9: Check "YES" if the patient's health condition is the same as it was prior to the vaccine, "NO" if the patient has not returned to the pre-vaccination state of health, or "UNKNOWN" if the patient's condition is not known.
- Item 10: Give dates and times as specifically as you can remember. If you do not know the exact time, please
- and 11: indicate "AM" or "PM" when possible if this information is known. If more than one adverse event, give the onset date and time for the most serious event.
- Item 12: Include "negative" or "normal" results of any relevant tests performed as well as abnormal findings.
- Item 13: List ONLY those vaccines given on the day listed in Item 10.
- Item 14: List any other vaccines that the patient received within 4 weeks prior to the date listed in Item 10.
- Item 16: This section refers to how the person who gave the vaccine purchased it, not to the patient's insurance.
- Item 17: List any prescription or non-prescription medications the patient was taking when the vaccine(s) was given.
- Item 18: List any short term illnesses the patient had on the date the vaccine(s) was given (i.e., cold, flu, ear infection).
- Item 19: List any pre-existing physician-diagnosed allergies, birth defects, medical conditions (including developmental and/or neurologic disorders) for the patient.
- Item 21: List any suspected adverse events the patient, or the patient's brothers or sisters, may have had to previous vaccinations. If more than one brother or sister, or if the patient has reacted to more than one prior vaccine, use additional pages to explain completely. For the onset age of a patient, provide the age in months if less than two years old.
- Item 26: This space is for manufacturers' use only.

Vaccine Injury Compensation Program (VICP)

The VICP is a no-fault alternative to the traditional tort system for resolving vaccine injury claims. It was established as part of the National Childhood Vaccine Injury Act of 1986, after a rash of lawsuits against vaccine manufacturers and healthcare providers threatened to cause vaccine shortages and reduce vaccination rates.

The VICP covers all vaccines recommended by the Centers for Disease Control and Prevention for routine administration to children. It is administered jointly by the U.S. Department of Health and Human Services (HHS), the U.S. Court of Federal Claims (the Court), and the U.S. Department of Justice (DOJ). The VICP is located in the HRSA Healthcare Systems Bureau. Covered vaccines and compensable injuries are described on the "Vaccine Injury Table" (see following page - F7).

The Claims Process

An individual claiming a vaccine-related injury or death files a petition for compensation with the Court, and may be represented by an attorney. The Secretary of HHS is named as the Respondent.

An HHS physician reviews the petition to determine whether it meets the medical criteria for compensation. This recommendation is provided to the Court through a Respondent's report filed by the DOJ. The HHS position is presented by an attorney from the DOJ in hearings before a "special master," who makes the decision for compensation under the VICP. A decision may be appealed to the Court, then to the Federal Circuit Court of Appeals, and eventually to the U.S. Supreme Court.

If a case is found eligible for compensation, the amount of the award is usually negotiated between the DOJ and the petitioner's attorneys. If the attorneys can't agree, the case is scheduled for a hearing for the special master to assess the amount of compensation. Compensable claims, and even most claims found to be non-compensable, are awarded reimbursement for attorney's fees and costs. A petitioner may file a claim in civil court against the vaccine company and/or the vaccine administrator only after first filing a claim under the VICP and then rejecting the decision of the Court.

For more information, including information about restrictions that apply to filing a petition, visit the VICP website at <http://www.hrsa.gov/vaccinecompensation> or phone 1-800-338-2382.

F For information on the Rules of the Court, including requirements for filing a petition, visit the Court's Website at <http://www.uscfc.uscourts.gov/osmPage.htm> or phone (202) 357-6400.

This information has been adapted from the VICP website (<http://www.hrsa.gov/vaccinecompensation>)

National Childhood Vaccine Injury Act: Vaccine Injury Table^a

Vaccine	Adverse Event	Time Interval
I Tetanus toxoid-containing vaccines (e.g., DTaP, Tdap, DTP-Hib, DT, Td, TT)	A Anaphylaxis or anaphylactic shock	0-4 hours
	B Brachial neuritis	2-28 days
	C Any acute complication or sequela (including death) of above events	Not applicable
II Pertussis antigen-containing vaccines (e.g., DTaP, Tdap, DTP, P, DTP-Hib)	A Anaphylaxis or anaphylactic shock	0-4 hours
	B Encephalopathy (or encephalitis)	0-72 hours
	C Any acute complication or sequela (including death) of above events	Not applicable
III Measles, mumps and rubella virus-containing vaccines in any combination (e.g., MMR, MR, M, R)	A Anaphylaxis or anaphylactic shock	0-4 hours
	B Encephalopathy (or encephalitis)	5-15 days
	C Any acute complication or sequela (including death) of above events	Not applicable
IV Rubella virus-containing vaccines (e.g., MMR, MR, R)	A Chronic arthritis	7-42 days
	B Any acute complication or sequela (including death) of above event	Not applicable
V Measles virus-containing vaccines (e.g., MMR, MR, M)	A Thrombocytopenic purpura	7-30 days
	B Vaccine-Strain Measles Viral Infection in an immunodeficient recipient	0-6 months
	C Any acute complication or sequela (including death) of above events	Not applicable
VI Polio live virus-containing vaccines (OPV)	A Paralytic polio - in a non-immunodeficient recipient - in an immunodeficient recipient - in a vaccine assoc. community case	0-30 days 0-6 months Not applicable
	B Vaccine-strain polio viral infection - in a non-immunodeficient recipient - in an immunodeficient recipient - in a vaccine assoc. community case	0-30 days 0-6 months Not applicable
	C Any acute complication or sequela (including death) of above events	Not applicable
VII Polio inactivated-virus containing vaccines (e.g., IPV)	A Anaphylaxis or anaphylactic shock	0-4 hours
	B Any acute complication or sequela (including death) of above event	Not applicable
VIII Hepatitis B antigen-containing vaccines	A Anaphylaxis or anaphylactic shock	0-4 hours
	B Any acute complication or sequela (including death) of above event	Not applicable
IX <i>Haemophilus influenzae</i> type b polysaccharide conjugate vaccines	A No condition specified for compensation	Not applicable
X Varicella vaccine	A No condition specified for compensation	Not applicable
XI Rotavirus vaccine	A No condition specified for compensation	Not applicable
XII Vaccines containing live, oral, rhesus-based rotavirus	A Intussusception	0-30 days
	B Any acute complication or sequela (including death) of above event	Not applicable
XIII Pneumococcal conjugate vaccines	A No condition specified for compensation	Not applicable
XIV Any new vaccine recommended by the Centers for Disease Control and Prevention for routine administration to children, after publication by Secretary, HHS of a notice of coverage ^{bc}	A No condition specified for compensation	Not applicable

^a Effective date: February 1, 2007

^b As of **December 1, 2004**, hepatitis A vaccines have been added to the Vaccine Injury Table (Table) under this Category. As of **July 1, 2005**, *trivalent* influenza vaccines have been added to the Table under this Category. Trivalent influenza vaccines are given annually during the flu season either by needle and syringe or in a nasal spray. All influenza vaccines routinely administered in the U.S. are trivalent vaccines covered under this Category.

^c As of **February 1, 2007**, meningococcal (conjugate and polysaccharide) and human papillomavirus (HPV) vaccines have been added to the Table under this category.

See *News* on the VICP website for more information (www.hrsa.gov/vaccinecompensation).

Qualifications and Aids to Interpretation

- (1) **Anaphylaxis and anaphylactic shock** mean an acute, severe, and potentially lethal systemic allergic reaction. Most cases resolve without sequelae. Signs and symptoms begin minutes to a few hours after exposure. Death, if it occurs, usually results from airway obstruction caused by laryngeal edema or bronchospasm and may be associated with cardiovascular collapse. Other significant clinical signs and symptoms may include the following: Cyanosis, hypotension, bradycardia, tachycardia, arrhythmia, edema of the pharynx and/or trachea and/or larynx with stridor and dyspnea. Autopsy findings may include acute emphysema which results from lower respiratory tract obstruction, edema of the hypopharynx, epiglottis, larynx, or trachea and minimal findings of eosinophilia in the liver, spleen and lungs. When death occurs within minutes of exposure and without signs of respiratory distress, there may not be significant pathologic findings.
- (2) **Encephalopathy.** For purposes of the Vaccine Injury Table, a vaccine recipient shall be considered to have suffered an encephalopathy only if such recipient manifests, within the applicable period, an injury meeting the description below of an acute encephalopathy, and then a chronic encephalopathy persists in such person for more than 6 months beyond the date of vaccination.
- (i) An acute encephalopathy is one that is sufficiently severe so as to require hospitalization (whether or not hospitalization occurred).
- (A) For children less than 18 months of age who present without an associated seizure event, an acute encephalopathy is indicated by a "significantly decreased level of consciousness" (see "D" below) lasting for at least 24 hours. Those children less than 18 months of age who present following a seizure shall be viewed as having an acute encephalopathy if their significantly decreased level of consciousness persists beyond 24 hours and cannot be attributed to a postictal state (seizure) or medication.
- (B) For adults and children 18 months of age or older, an acute encephalopathy is one that persists for at least 24 hours and characterized by at least two of the following:
- (1) A significant change in mental status that is not medication related; specifically a confusional state, or a delirium, or a psychosis;
 - (2) A significantly decreased level of consciousness, which is independent of a seizure and cannot be attributed to the effects of medication; and
 - (3) A seizure associated with loss of consciousness.
- (C) Increased intracranial pressure may be a clinical feature of acute encephalopathy in any age group.
- (D) A "significantly decreased level of consciousness" is indicated by the presence of at least one of the following clinical signs for at least 24 hours or greater (see paragraphs (2)(I)(A) and (2)(I)(B) of this section for applicable timeframes):
- (1) Decreased or absent response to environment (responds, if at all, only to loud voice or painful stimuli);
 - (2) Decreased or absent eye contact (does not fix gaze upon family members or other individuals); or
 - (3) Inconsistent or absent responses to external stimuli (does not recognize familiar people or things).
- (E) The following clinical features alone, or in combination, do not demonstrate an acute encephalopathy or a significant change in either mental status or level of consciousness as described above: Sleepiness, irritability (fussiness), high-pitched and unusual screaming, persistent inconsolable crying, and bulging fontanelle. Seizures in themselves are not sufficient to constitute a diagnosis of encephalopathy. In the absence of other evidence of an acute encephalopathy, seizures shall not be viewed as the first symptom or manifestation of the onset of an acute encephalopathy.
- (ii) Chronic encephalopathy occurs when a change in mental or neurologic status, first manifested during

the applicable time period, persists for a period of at least 6 months from the date of vaccination. Individuals who return to a normal neurologic state after the acute encephalopathy shall not be presumed to have suffered residual neurologic damage from that event; any subsequent chronic encephalopathy shall not be presumed to be a sequela of the acute encephalopathy. If a preponderance of the evidence indicates that a child's chronic encephalopathy is secondary to genetic, prenatal or perinatal factors, that chronic encephalopathy shall not be considered to be a condition set forth in the Table.

- (iii) An encephalopathy shall not be considered to be a condition set forth in the Table if in a proceeding on a petition, it is shown by a preponderance of the evidence that the encephalopathy was caused by an infection, a toxin, a metabolic disturbance, a structural lesion, a genetic disorder or trauma (without regard to whether the cause of the infection, toxin, trauma, metabolic disturbance, structural lesion or genetic disorder is known). If at the time a decision is made on a petition filed under section 2111(b) of the Act for a vaccine-related injury or death, it is not possible to determine the cause by a preponderance of the evidence of an encephalopathy, the encephalopathy shall be considered to be a condition set forth in the Table.
- (iv) In determining whether or not an encephalopathy is a condition set forth in the Table, the Court shall consider the entire medical record.
- 3) **Seizure and convulsion.** For purposes of paragraphs (b)(2) of this section, the terms, "seizure" and "convulsion" include myoclonic, generalized tonic-clonic (grand mal), and simple and complex partial seizures. Absence (petit mal) seizures shall not be considered to be a condition set forth in the Table. Jerking movements or staring episodes alone are not necessarily an indication of seizure activity.
- (4) **Sequela.** The term "sequela" means a condition or event which was actually caused by a condition listed in the Vaccine Injury Table.
- (5) **Chronic Arthritis.** For purposes of the Vaccine Injury Table, chronic arthritis may be found in a person with no history in the 3 years prior to vaccination of arthropathy (joint disease) on the basis of:
 - (A) Medical documentation, recorded within 30 days after the onset, of objective signs of acute arthritis (joint swelling) that occurred between 7 and 42 days after a rubella vaccination;
 - (B) Medical documentation (recorded within 3 years after the onset of acute arthritis) of the persistence of objective signs of intermittent or continuous arthritis for more than 6 months following vaccination;
 - (C) Medical documentation of an antibody response to the rubella virus.

For purposes of the Vaccine Injury Table, the following shall not be considered as chronic arthritis: Musculoskeletal disorders such as diffuse connective tissue diseases (including but not limited to rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disease, polymyositis/dermatomyositis, fibromyalgia, necrotizing vasculitis and vasculopathies and Sjogren's Syndrome), degenerative joint disease, infectious agents other than rubella (whether by direct invasion or as an immune reaction), metabolic and endocrine diseases, trauma, neoplasms, neuropathic disorders, bone and cartilage disorders and arthritis associated with ankylosing spondylitis, psoriasis, inflammatory bowel disease, Reiter's syndrome, or blood disorders. Arthralgia (joint pain) or stiffness without joint swelling shall not be viewed as chronic arthritis for purposes of the Vaccine Injury Table.

- (6) **Brachial neuritis** is defined as dysfunction limited to the upper extremity nerve plexus (i.e., its trunks, divisions, or cords) without involvement of other peripheral (e.g., nerve roots or a single peripheral nerve) or central (e.g., spinal cord) nervous system structures. A deep, steady, often severe aching pain in the shoulder and upper arm usually heralds onset of the condition. The pain is followed in days or weeks by weakness and atrophy in upper extremity muscle groups. Sensory loss may accompany the motor deficits, but is generally a less notable clinical feature. The neuritis, or plexopathy, may be present on the same side as or the opposite side of the injection; it is sometimes bilateral, affecting both upper extremities. Weakness is required before the diagnosis can be made. Motor, sensory, and reflex findings on physical examination and the results of nerve conduction and electromyographic studies must be consistent in con-

firming that dysfunction is attributable to the brachial plexus. The condition should thereby be distinguishable from conditions that may give rise to dysfunction of nerve roots (i.e., radiculopathies) and peripheral nerves (i.e., including multiple mononeuropathies), as well as other peripheral and central nervous system structures (e.g., cranial neuropathies and myelopathies).

- (7) **Thrombocytopenic purpura** is defined by a serum platelet count less than $50,000/\text{mm}^3$. Thrombocytopenic purpura does not include cases of thrombocytopenia associated with other causes such as hypersplenism, autoimmune disorders (including alloantibodies from previous transfusions) myelodysplasias, lymphoproliferative disorders, congenital thrombocytopenia or hemolytic uremic syndrome. This does not include cases of immune (formerly called idiopathic) thrombocytopenic purpura (ITP) that are mediated, for example, by viral or fungal infections, toxins or drugs. Thrombocytopenic purpura does not include cases of thrombocytopenia associated with disseminated intravascular coagulation, as observed with bacterial and viral infections. Viral infections include, for example, those infections secondary to Epstein Barr virus, cytomegalovirus, hepatitis A and B, rhinovirus, human immunodeficiency virus (HIV), adenovirus, and dengue virus. An antecedent viral infection may be demonstrated by clinical signs and symptoms and need not be confirmed by culture or serologic testing. Bone marrow examination, if performed, must reveal a normal or an increased number of megakaryocytes in an otherwise normal marrow.
- (8) **Vaccine-strain measles viral infection** is defined as a disease caused by the vaccine-strain that should be determined by vaccine specific monoclonal antibody or polymerase chain reaction tests.
- (9) **Vaccine-strain polio viral infection** is defined as a disease caused by poliovirus that is isolated from the affected tissue and should be determined to be the vaccine-strain by oligonucleotide or polymerase chain reaction. Isolation of poliovirus from the stool is not sufficient to establish a tissue specific infection or disease caused by vaccine-strain poliovirus.